A phase 1b study of abemaciclib, an inhibitor of CDK4 and...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer

Beeram, M., Tolaney, S.M., Beck, J.T., Dickler, M.N., Conlin, A.K., Dees, C., Helsten, T.L., Conkling, P.R., Edenfield, W.J., Richards, D.A., Kambhampati, S.R.P., Costigan, T.M., Chan, E., Pant, S., K
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw435.08
Date:
October, 2016
File:
PDF, 43 KB
english, 2016
Conversion to is in progress
Conversion to is failed